Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

Pavlo Gilchuk, Natalia Kuzmina, Philipp A. Ilinykh, Kai Huang, Bronwyn M. Gunn, Aubrey Bryan, Edgar Davidson, Benjamin J. Doranz, Hannah L. Turner, Marnie L. Fusco, Matthew S. Bramble, Nicole A. Hoff, Elad Binshtein, Nurgun Kose, Andrew I. Flyak, Robin Flinko, Chiara Orlandi, Robert Carnahan, Erica H. Parrish, Alexander M. Sevy & 12 others Robin G. Bombardi, Prashant K. Singh, Patrick Mukadi, Jean Jacques Muyembe-Tamfum, Melanie D. Ohi, Erica Ollmann Saphire, George K. Lewis, Galit Alter, Andrew B. Ward, Anne W. Rimoin, Alexander Bukreyev, James E. Crowe

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules. Ebola virus, a member of the Filoviridae family, causes severe disease in humans. Gilchuk et al. isolated and characterized broadly neutralizing human monoclonal antibodies active against all three clinically relevant ebolavirus species. Potent monoclonal antibody EBOV-520 binds to the glycoprotein base region, acts principally by direct virus neutralization, and exploits several mechanisms for contributing to pan-ebolavirus protective immunity.

Original languageEnglish (US)
Pages (from-to)363-374.e10
JournalImmunity
Volume49
Issue number2
DOIs
StatePublished - Aug 21 2018

Fingerprint

Ebolavirus
Glycoproteins
Antibodies
Monoclonal Antibodies
Viruses
Filoviridae
Forensic Anthropology
Sudan
Antibody Formation
Survivors
Epitopes
Immunity
Animal Models
Clone Cells

Keywords

  • cross protection
  • Ebola hemorrhagic fever
  • ebolavirus
  • epitope mapping
  • epitopes
  • glycoproteins
  • heterologous immunity
  • monoclonal antibodies
  • neutralizing antibodies
  • viral antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. / Gilchuk, Pavlo; Kuzmina, Natalia; Ilinykh, Philipp A.; Huang, Kai; Gunn, Bronwyn M.; Bryan, Aubrey; Davidson, Edgar; Doranz, Benjamin J.; Turner, Hannah L.; Fusco, Marnie L.; Bramble, Matthew S.; Hoff, Nicole A.; Binshtein, Elad; Kose, Nurgun; Flyak, Andrew I.; Flinko, Robin; Orlandi, Chiara; Carnahan, Robert; Parrish, Erica H.; Sevy, Alexander M.; Bombardi, Robin G.; Singh, Prashant K.; Mukadi, Patrick; Muyembe-Tamfum, Jean Jacques; Ohi, Melanie D.; Saphire, Erica Ollmann; Lewis, George K.; Alter, Galit; Ward, Andrew B.; Rimoin, Anne W.; Bukreyev, Alexander; Crowe, James E.

In: Immunity, Vol. 49, No. 2, 21.08.2018, p. 363-374.e10.

Research output: Contribution to journalArticle

Gilchuk, P, Kuzmina, N, Ilinykh, PA, Huang, K, Gunn, BM, Bryan, A, Davidson, E, Doranz, BJ, Turner, HL, Fusco, ML, Bramble, MS, Hoff, NA, Binshtein, E, Kose, N, Flyak, AI, Flinko, R, Orlandi, C, Carnahan, R, Parrish, EH, Sevy, AM, Bombardi, RG, Singh, PK, Mukadi, P, Muyembe-Tamfum, JJ, Ohi, MD, Saphire, EO, Lewis, GK, Alter, G, Ward, AB, Rimoin, AW, Bukreyev, A & Crowe, JE 2018, 'Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein', Immunity, vol. 49, no. 2, pp. 363-374.e10. https://doi.org/10.1016/j.immuni.2018.06.018
Gilchuk, Pavlo ; Kuzmina, Natalia ; Ilinykh, Philipp A. ; Huang, Kai ; Gunn, Bronwyn M. ; Bryan, Aubrey ; Davidson, Edgar ; Doranz, Benjamin J. ; Turner, Hannah L. ; Fusco, Marnie L. ; Bramble, Matthew S. ; Hoff, Nicole A. ; Binshtein, Elad ; Kose, Nurgun ; Flyak, Andrew I. ; Flinko, Robin ; Orlandi, Chiara ; Carnahan, Robert ; Parrish, Erica H. ; Sevy, Alexander M. ; Bombardi, Robin G. ; Singh, Prashant K. ; Mukadi, Patrick ; Muyembe-Tamfum, Jean Jacques ; Ohi, Melanie D. ; Saphire, Erica Ollmann ; Lewis, George K. ; Alter, Galit ; Ward, Andrew B. ; Rimoin, Anne W. ; Bukreyev, Alexander ; Crowe, James E. / Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. In: Immunity. 2018 ; Vol. 49, No. 2. pp. 363-374.e10.
@article{4c157c196fa34e2a9ab4ab61a8f4f52b,
title = "Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein",
abstract = "Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules. Ebola virus, a member of the Filoviridae family, causes severe disease in humans. Gilchuk et al. isolated and characterized broadly neutralizing human monoclonal antibodies active against all three clinically relevant ebolavirus species. Potent monoclonal antibody EBOV-520 binds to the glycoprotein base region, acts principally by direct virus neutralization, and exploits several mechanisms for contributing to pan-ebolavirus protective immunity.",
keywords = "cross protection, Ebola hemorrhagic fever, ebolavirus, epitope mapping, epitopes, glycoproteins, heterologous immunity, monoclonal antibodies, neutralizing antibodies, viral antibodies",
author = "Pavlo Gilchuk and Natalia Kuzmina and Ilinykh, {Philipp A.} and Kai Huang and Gunn, {Bronwyn M.} and Aubrey Bryan and Edgar Davidson and Doranz, {Benjamin J.} and Turner, {Hannah L.} and Fusco, {Marnie L.} and Bramble, {Matthew S.} and Hoff, {Nicole A.} and Elad Binshtein and Nurgun Kose and Flyak, {Andrew I.} and Robin Flinko and Chiara Orlandi and Robert Carnahan and Parrish, {Erica H.} and Sevy, {Alexander M.} and Bombardi, {Robin G.} and Singh, {Prashant K.} and Patrick Mukadi and Muyembe-Tamfum, {Jean Jacques} and Ohi, {Melanie D.} and Saphire, {Erica Ollmann} and Lewis, {George K.} and Galit Alter and Ward, {Andrew B.} and Rimoin, {Anne W.} and Alexander Bukreyev and Crowe, {James E.}",
year = "2018",
month = "8",
day = "21",
doi = "10.1016/j.immuni.2018.06.018",
language = "English (US)",
volume = "49",
pages = "363--374.e10",
journal = "Immunity",
issn = "1074-7613",
publisher = "Cell Press",
number = "2",

}

TY - JOUR

T1 - Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein

AU - Gilchuk, Pavlo

AU - Kuzmina, Natalia

AU - Ilinykh, Philipp A.

AU - Huang, Kai

AU - Gunn, Bronwyn M.

AU - Bryan, Aubrey

AU - Davidson, Edgar

AU - Doranz, Benjamin J.

AU - Turner, Hannah L.

AU - Fusco, Marnie L.

AU - Bramble, Matthew S.

AU - Hoff, Nicole A.

AU - Binshtein, Elad

AU - Kose, Nurgun

AU - Flyak, Andrew I.

AU - Flinko, Robin

AU - Orlandi, Chiara

AU - Carnahan, Robert

AU - Parrish, Erica H.

AU - Sevy, Alexander M.

AU - Bombardi, Robin G.

AU - Singh, Prashant K.

AU - Mukadi, Patrick

AU - Muyembe-Tamfum, Jean Jacques

AU - Ohi, Melanie D.

AU - Saphire, Erica Ollmann

AU - Lewis, George K.

AU - Alter, Galit

AU - Ward, Andrew B.

AU - Rimoin, Anne W.

AU - Bukreyev, Alexander

AU - Crowe, James E.

PY - 2018/8/21

Y1 - 2018/8/21

N2 - Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules. Ebola virus, a member of the Filoviridae family, causes severe disease in humans. Gilchuk et al. isolated and characterized broadly neutralizing human monoclonal antibodies active against all three clinically relevant ebolavirus species. Potent monoclonal antibody EBOV-520 binds to the glycoprotein base region, acts principally by direct virus neutralization, and exploits several mechanisms for contributing to pan-ebolavirus protective immunity.

AB - Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules. Ebola virus, a member of the Filoviridae family, causes severe disease in humans. Gilchuk et al. isolated and characterized broadly neutralizing human monoclonal antibodies active against all three clinically relevant ebolavirus species. Potent monoclonal antibody EBOV-520 binds to the glycoprotein base region, acts principally by direct virus neutralization, and exploits several mechanisms for contributing to pan-ebolavirus protective immunity.

KW - cross protection

KW - Ebola hemorrhagic fever

KW - ebolavirus

KW - epitope mapping

KW - epitopes

KW - glycoproteins

KW - heterologous immunity

KW - monoclonal antibodies

KW - neutralizing antibodies

KW - viral antibodies

UR - http://www.scopus.com/inward/record.url?scp=85053075312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053075312&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2018.06.018

DO - 10.1016/j.immuni.2018.06.018

M3 - Article

VL - 49

SP - 363-374.e10

JO - Immunity

JF - Immunity

SN - 1074-7613

IS - 2

ER -